Market Research Logo

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2025

Summary

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. Today, HER2-positive breast cancer patients are living longer with their disease, thanks to established disease management strategies using numerous combinations of chemotherapy with Herceptin, Perjeta, and the tyrosine kinase inhibitor (TKI) Tykerb (lapatinib). During the forecast period from 2015-2025, GlobalData expects that the HER2-positive market will grow due to the launch of HER2-targeted agents in the early disease setting and the aging populations in the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan, and China.

Following the patent expiry of Herceptin and the subsequent highly anticipated introduction of trastuzumab biosimilars during the forecast period, the market is expected to face its biggest barrier to growth to date. Despite a lack of game-changing innovation in the HER2-positive market, the pipeline is diverse with several agents being investigated in the extended adjuvant and metastatic settings. A number of these agents are looking to address the greatest unmet need for HER2-positive breast cancer patients-brain metastases-which typically occur in the later lines of metastatic therapy and are caused by increasingly resistant disease.

Key Questions Answered

  • How will biosimilar penetration impact the HER2-positive breast cancer market, especially following the launch of trastuzumab biosimilars in the 8MM?
  • How will new pipeline agents such as Ibrance and neratinib impact the HER2-positive breast cancer market?
  • The HER2-positive breast cancer market is characterized by a number of unmet needs in the current treatments. What are the main unmet needs in this market? Will the pipeline drugs under development fulfil these unmet needs?
  • What impact will the approval of Roche’s Perjeta in the adjuvant setting following data from the Aphinity trial have on the HER2-positive breast cancer market? What will be the drug’s peak sales, and why?
Scope
  • Overview of HER2-positive breast cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized HER2-positive breast cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in nine patient segments and two treatment strategies (episodic and prophylactic treatment), forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HER2-positive breast cancer therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for HER2-positive breast cancer. The most promising candidate in Phase III development is profiled.
  • Analysis of the current and future market competition in the global HER2-positive breast cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global HER2-positive breast cancer market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2-positive breast cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 HER2-Positive Breast Cancer Market to Increase by 50% by 2025
2.2 Perjeta Will Be the Strongest Driver of Market Growth
2.3 The Launch of Biosimilar Trastuzumab
2.4 Roche Will Continue to Monopolize the HER2-Positive Breast Cancer Market, Despite Herceptin Patent Loss
2.5 Improved Treatment for Brain Metastases Remains a Pressing Unmet Need
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Basic Breast Anatomy
4.3 Breast Cancer Staging
4.4 Prognosis
4.5 Quality of Life
4.6 Symptoms
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global Trends
5.3.1 US
5.3.2 5EU
5.3.3 Japan
5.3.4 China (Urban)
5.3.5 Prevalence and Survival
5.4 Forecast Methodology
5.4.1 Sources Used Tables
5.4.2 Forecast Assumptions and Methods
5.4.3 Sources Not Used
5.5 Epidemiological Forecast for Non-Invasive DCIS Breast Cancer (2015-2025)
5.5.1 Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer
5.5.2 Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status
5.6 Epidemiological Forecast for Invasive Breast Cancer (2015-2025)
5.6.1 Diagnosed Incident Cases of Invasive Breast Cancer
5.6.2 Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer
5.6.3 Age-Standardized Diagnosed Incidence of Invasive Breast Cancer
5.6.4 Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer
5.6.5 Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis
5.6.6 Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status
5.6.7 Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Stage at Diagnosis, Menopausal Status, and Site of Metastasis
5.6.8 Diagnosed Incident Cases of HER2-/HR+ Breast Cancer by Stage at Diagnosis, Menopausal Status, and Type of Biomarker Expression
5.6.9 Diagnosed Incident Cases of TN Breast Cancer by Stage at Diagnosis and BRCA Expression
5.7 Discussion
5.7.1 Epidemiological Forecast Insight
5.7.2 Limitations of the Analysis
5.7.3 Strengths of the Analysis
6 Disease Management
6.1 Treatment Overview
6.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB)
6.1.2 Treatment of Locally Advanced and Regional Breast Cancer (Stage IB to IIIA)
6.1.3 Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV)
6.2 US
6.2.1 Diagnosis
6.2.2 Clinical Practice
6.3 France
6.3.1 Diagnosis
6.3.2 Clinical Practice
6.4 Germany
6.4.1 Diagnosis
6.4.2 Clinical Practice
6.5 Italy
6.5.1 Diagnosis
6.5.2 Clinical Practice
6.6 Spain
6.6.1 Diagnosis
6.6.2 Clinical Practice
6.7 UK
6.7.1 Diagnosis
6.7.2 Clinical Practice
6.8 Japan
6.8.1 Diagnosis
6.8.2 Clinical Practice
6.9 China
6.9.1 Diagnosis
6.9.2 Clinical Practice
7 Competitive Assessment
7.1 Overview
7.2 Product Profiles - HER2-Targeted Therapies
7.2.1 Herceptin (Trastuzumab)
7.2.2 Tykerb (Lapatinib)
7.2.3 Perjeta (Pertuzumab)
7.2.4 Kadcyla (Ado-trastuzumab Emtansine, T-DM1)
7.3 Product Profiles - General Targeted Therapies
7.3.1 Halaven (Eribulin Mesylate)
7.3.2 Abraxane (Nab-Paclitaxel)
7.3.3 Ixempra (Ixabepilone)
7.4 Hormonal Agents
7.4.1 Tamoxifen
7.4.2 Faslodex (Fulvestrant)
7.4.3 Aromatase Inhibitors
8 Unmet Need and Opportunity
8.1 Overview
8.2 Treatment of Brain/CNS Metastases
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.2.3 Opportunity
8.3 Resistance to HER2-Targeted Therapies
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.3.3 Opportunity
8.4 Effective Alternatives to Chemotherapy
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.4.3 Opportunity
9 Pipeline Assessment
9.1 Overview
9.2 HER2-Targeted Therapies
9.2.1 Neratinib
9.2.2 Margetuximab
9.2.3 Tucatinib (ONT-380)
9.2.4 Pyrotinib
9.3 Other Therapies
9.3.1 Utidelone (Depoxythilone; UTD-1)
9.3.2 Ibrance (Palbociclib)
9.3.3 Onzeald (Etirinotecan Pegol)
9.4 Drugs in Early-Stage Development
9.4.1 Abemaciclib
9.4.2 Adagloxad Simolenin (OBI-822/821)
9.4.3 Patritumab
9.4.4 NeuVax (nelipepimut-S)
9.4.5 Alpelisib
9.4.6 Buparlisib
9.4.7 Xtandi (Enzalutamide)
9.4.8 DS-8201a
9.5 Biosimilars
9.5.1 Overview
9.5.2 Nomenclature
9.5.3 EU
9.5.4 US
9.5.5 Japan
9.5.6 China
9.5.7 Ex-8MM Trastuzumab Biosimilars
9.5.8 Ongoing 8MM Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Roche/Genentech
10.3.2 Novartis
10.3.3 Pfizer
10.3.4 Puma Biotechnology
10.3.5 The Biosimilar Players
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
11.5 China
11.5.1 Forecast
11.5.2 Key Events
11.5.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.4 Forecasting Methodology
12.4.1 Diagnosed Patients with HER2-Positive Breast Cancer
12.4.2 Percent Drug-Treated Patients
12.4.3 Drugs Included in Each Therapeutic Class
12.4.4 Launch and Patent Expiration Dates
12.4.5 General Pricing Assumptions
12.4.6 Average Body Weight and Surface Area Across the 8MM
12.4.7 General Forecast Assumptions
12.4.8 Individual Drug Assumptions
12.4.9 Generic Erosion
12.4.10 Pricing of Pipeline Agents
12.5 Primary Research - KOLs Interviewed for this Report
12.6 Primary Research - Prescriber Survey
12.7 About the Authors
12.7.1 Analysts
12.7.2 Epidemiologist
12.7.3 Therapy Area Director
12.7.4 Epidemiology Director
12.7.5 Global Director of Therapy Analysis and Epidemiology
12.7.6 Global Head of Healthcare
12.8 About GlobalData
12.9 Contact Us
12.10 Disclaimer
1.1 List of Tables
Table 1: HER2-Positive Breast Cancer: Key Metrics in the Eight Major Pharmaceutical Markets, 2015-2025
Table 2: Definitions of HER2 Status by IHC Staining
Table 3: AJCC Stage Definitions for Breast Cancer
Table 4: Prognosis for Breast Cancer in the US
Table 5: Risk Factors and Comorbidities for Breast Cancer
Table 6: 8MM, Most Recent Five-Year Relative Survival for Invasive Breast Cancer, Women (%)
Table 7: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Non-Invasive DCIS Breast Cancer
Table 8: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status
Table 9: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Invasive Breast Cancer
Table 10: 8MM, Sources of Epidemiological Data Used to Forecast Invasive Breast Cancer by HER2 Status
Table 11: 8MM, Sources of Epidemiological Data Used to Forecast the Relative Survival of Invasive Breast Cancer
Table 12: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Stage at Diagnosis
Table 13: 8MM, Sources of Epidemiological Data Used to Forecast HER2-, HR+ Invasive Breast Cancer by Stage at Diagnosis
Table 14: 8MM, Sources of Epidemiological Data Used to Forecast TN Invasive Breast Cancer by Stage at Diagnosis
Table 15: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Menopausal Status
Table 16: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Site of Metastasis
Table 17: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Type of Biomarker Expression
Table 18: 8MM, Sources Not Used in Epidemiological Analysis of Breast Cancer
Table 19: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages ≥18 Years, N, Select Years, 2015-2025
Table 20: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages ≥18 Years, N, 2015
Table 21: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages ≥18 Years, N, Select Years, 2015-2025
Table 22: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages ≥18 Years, N (Row %), 2015
Table 23: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages ≥18 Years, N, Select Years, 2015-2025
Table 24: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages ≥18 Years, N, 2015
Table 25: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status, Women, Ages ≥18 Years, N, 2015
Table 26: Treatment Guidelines for HER2-Positive Breast Cancer
Table 27: Product Profile - Herceptin
Table 28: Clinical Studies for Herceptin in the Adjuvant Setting
Table 29: Efficacy of Herceptin + chemotherapy in untreated metastatic HER2-positive breast cancer
Table 30: Safety of Herceptin Monotherapy in Early-Stage HER2-Positive Breast Cancer
Table 31: Safety Profile of Herceptin + Chemotherapy in Untreated Metastatic HER2-Positive Breast Cancer
Table 32: Herceptin SWOT Analysis, 2017
Table 33: Product Profile - Tykerb
Table 34: Efficacy of Tykerb in Combination with Capecitabine for the Second-line Treatment of HER2-Positive Metastatic Breast Cancer
Table 35: Safety Profile of Tykerb in Combination with Capecitabine for the Treatment of Metastatic Breast Cancer
Table 36: Safety Profile of Tykerb in Combination with Letrozole for the Treatment of Metastatic Breast Cancer
Table 37: Tykerb SWOT Analysis, 2017
Table 38: Product Profile - Perjeta
Table 39: Efficacy of Perjeta in Combination with Herceptin and docetaxel for the Treatment of HER2-positive Metastatic Breast Cancer (CLEOPATRA, NCT00567190)
Table 40: Efficacy of Perjeta in Combination with Herceptin and docetaxel for the Treatment of Locally Advanced HER2-positive Breast Cancer (NeoSphere, NCT00545688)
Table 41: Safety Profile of Perjeta in Combination with Herceptin and Docetaxel for the Treatment of Metastatic Breast Cancer (CLEOPATRA, NCT00567190)
Table 42: Perjeta SWOT Analysis, 2017
Table 43: Product Profile - Kadcyla
Table 44: Efficacy of Kadcyla Monotherapy for the Second-Line Treatment of HER2-Positive Metastatic Breast Cancer (EMILIA, NCT00829166)
Table 45: Safety Profile of Kadcyla Monotherapy for the Second-Line Treatment of HER2-Positive Metastatic Breast Cancer (EMILIA, NCT00829166)
Table 46: Kadcyla SWOT Analysis, 2017
Table 47: Product Profile - Halaven
Table 48: Efficacy of Halaven in the Treatment of Metastatic Breast Cancer (EMBRACE, NCT00388726)
Table 49: Efficacy of Halaven in the Second-Line Treatment of Metastatic Breast Cancer (Study 301, NCT00337103)
Table 50: Safety Profile of Halaven in the Third-line Treatment of Metastatic Breast Cancer (EMBRACE, NCT00388726)
Table 51: Halaven SWOT Analysis, 2017
Table 52: Product Profile - Abraxane
Table 53: Efficacy of Abraxane Monotherapy in the Treatment of Metastatic Breast Cancer
Table 54: Safety of Abraxane Monotherapy in the Treatment of Metastatic Breast Cancer
Table 55: Abraxane SWOT Analysis, 2017
Table 56: Product Profile - Ixempra
Table 57: Efficacy of Ixempra in Combination with Xeloda for the Treatment of Metastatic Breast Cancer
Table 58: Safety of Ixempra in Combination with Capecitabine for the Treatment of Metastatic Breast Cancer
Table 59: Ixempra SWOT Analysis, 2017
Table 60: Summary of Minor Therapeutic Classes Used to Treat HER2-Positive Breast Cancer, 2017
Table 61: Unmet Need and Opportunity in HER2-Positive Breast Cancer
Table 62: Product Profile - Neratinib
Table 63: Efficacy of Neratinib from the Phase III ExteNET Trial (Two-Year Data Set)
Table 64: Efficacy of Neratinib from the Phase III ExteNET Trial (Five-Year Data Set)
Table 65: Safety of Neratinib Monotherapy Compared to Placebo from the ExteNET trial in HER2-Positive Breast Cancer Patients Who Received Adjuvant Herceptin Therapy
Table 66: Treatment-Emergent Diarrhea from the Phase III CONTROL Trial
Table 67: Neratinib SWOT Analysis, 2016
Table 68: Product Profile - Margetuximab
Table 69: Safety of Margetuximab Monotherapy in Metastatic HER2-Positve Breast Cancer Patients
Table 70: Margetuximab SWOT Analysis
Table 71: Product Profile - ARRY-380
Table 72: Efficacy of Tucatinib from the Phase I Trial in HER2-Positive Metastatic Breast Cancer
Table 73: Safety Profile of Tucatinib Administered at the MTD (600mg or 650 mg BID) from the Phase I Trial in HER2-Positive Metastatic Solid Cancers
Table 74: Tucatinib SWOT Analysis
Table 75: Product Profile - Pyrotinib
Table 76: Efficacy of Pyrotinib from the Phase I Clinical Trial (NCT01937689)
Table 77: Pyrotinib SWOT Analysis, 2017
Table 78: Product Profile - Utidelone
Table 79: Efficacy of Utidelone as a Monotherapy and in Combination with Capecitabine in the Treatment of Metastatic Breast Cancer
Table 80: Safety of Utidelone in Combination with Capecitabine and as a Monotherapy for the Treatment of Metastatic Breast Cancer from the Phase II Trial (CHiCTR-TRC-13004205)
Table 81: Utidelone SWOT Analysis, 2017
Table 82: Product Profile - Ibrance
Table 83: Efficacy of Ibrance from the Phase II Study, NA-PHER2
Table 84: Efficacy of Ibrance from the Phase II Study (NCT01037790)
Table 85: Ibrance SWOT Analysis, 2017
Table 86: Product Profile - Onzeald
Table 87: Efficacy of Onzeald from the Phase III Study, BEACON
Table 88: Safety of Onzeald from the Phase III Study, BEACON
Table 89: Onzeald SWOT Analysis, 2017
Table 90: Comparison of Therapeutic Classes in Development for HER2-Positive/HER2-Negative Breast Cancer, 2017
Table 91: HER2-Positive Breast Cancer - Early-Phase Pipeline, 2017
Table 92: Safety of Adagloxad Simolenin in Combination with Cyclophosphamide for the Treatment of Metastatic Breast Cancer
Table 93: Trastuzumab Biosimilars, 2017
Table 94: Trastuzumab Biosimilars, 2016
Table 95: Key Companies in the HER2-Positive Breast Cancer Market in the 8MM, 2015-2025
Table 96: Roche’s HER2-Positive Breast Cancer Portfolio Assessment, 2017
Table 97: Roche SWOT Analysis, 2017
Table 98: Novartis’ HER2-Positive Breast Cancer Portfolio Assessment, 2017
Table 99: Novartis SWOT Analysis, 2017
Table 100: Pfizer’s HER2-Positive Breast Cancer Portfolio Assessment, 2017
Table 101: Pfizer SWOT Analysis, 2017
Table 102: Puma Biotechnology’s HER2-Positive Breast Cancer Portfolio Assessment, 2017
Table 103: Puma Biotechnology SWOT Analysis, 2017
Table 104: Mylan’s HER2-Positive Breast Cancer Portfolio Assessment, 2017
Table 105: Mylan/Biocon SWOT Analysis, 2017
Table 106: Teva’s HER2-Positive Breast Cancer Portfolio Assessment, 2017
Table 107: Teva/Celltrion SWOT Analysis, 2017
Table 108: Merck & Co.’s HER2-Positive Breast Cancer Portfolio Assessment, 2017
Table 109: Merck & Co./Samsung Bioepsis SWOT Analysis, 2017
Table 110: Global HER2-Positive Breast Cancer Market - Drivers and Barriers, 2015-2025
Table 111: Key Events Impacting Sales for HER2-Positive Breast Cancer in the US, 2015-2025
Table 112: US HER2-Positive Breast Cancer Market - Drivers and Barriers, 2015-2025
Table 113: Key Events Impacting Sales for HER2-Positive Breast Cancer in the 5EU, 2015-2025
Table 114: 5EU HER2-Positive Breast Cancer Market - Drivers and Barriers, 2015-2025
Table 115: Key Events Impacting Sales for HER2-Positive Breast Cancer in Japan, 2015-2025
Table 116: Japanese HER2-Positive Breast Cancer Market - Drivers and Barriers, 2015-2025
Table 117: Key Events Impacting Sales for HER2-Positive Breast Cancer in China, 2015-2025
Table 118: Chinese HER2-Positive Breast Cancer Market - Drivers and Barriers, 2015-2025
Table 119: Key Launch Dates in HER2-Positive Breast Cancer
Table 120: Key Patent/Exclusivity Expiries
Table 121: Average Body Weight and Surface Area Across the 8MM
Table 122: Average Cost of Therapy of Generic Chemotherapy in the 8MM
Table 123: Average Cost of Therapy of Liposomal Doxorubicin in the 8MM
Table 124: Cost of Therapy of Generic Capecitabine in the US
Table 125: Average Cost of Therapy of Herceptin in the 8MM
Table 126: Average Cost of Therapy of Perjeta in the 8MM
Table 127: Average Cost of Therapy of Tykerb/Tyverb in the 8MM
Table 128: Average Cost of Therapy of Kadcyla in the 8MM
Table 129: Average Cost of Endocrine Therapy in the 8MM
Table 130: Average Cost of Therapy of Faslodex in the 8MM
Table 131: Average Cost of Therapy of Halaven in the 8MM
Table 132: Average Cost of Therapy of Abraxane in the 8MM
Table 133: Average Cost of Therapy of Ixempra in the 8MM
Table 134: Average Cost of Therapy of Neratinib in the 8MM
Table 135: Average Cost of Therapy of Ibrance in the 8MM
Table 136: Average Cost of Therapy of Onzeald in the 8MM
Table 137: Average Cost of Therapy of Tucatinib in the 8MM
Table 138: Average Cost of Therapy of Margetuximab in the 8MM
Table 139: Average Cost of Therapy of Pyrotinib in the 8MM
Table 140: Average Cost of Therapy of UTD-1 in the 8MM
Table 141: High-Prescribing Physicians (non-KOLs) Surveyed, by Country
1.2 List of Figures
Figure 1: Global Sales for HER2-Positive Breast Cancer by Region, 2015-2025
Figure 2:Company Portfolio Gap Analysis in HER2-Positive Breast Cancer, 2015-2025
Figure 3: Competitive Assessment of Most Promising Agents for HER2-Positive Breast Cancer, 2015-2025
Figure 4: Basic Breast Anatomy, Including Key Lymph Nodes
Figure 5: 8MM, Crude Diagnosed Incidence Rates of Invasive Breast Cancer, Ages ≥18 Years, Women, Cases per 100,000 Population, 2005‒2014
Figure 6: Case Flow Map
Figure 7: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages ≥18 Years, Selected Years, 2015-2025
Figure 8: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages ≥18 Years, 2015
Figure 9: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages ≥18 Years, Selected Years, 2015-2025
Figure 10: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages ≥18 Years, N, 2015
Figure 11: 8MM, Age-Standardized Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages ≥18 Years, N, 2015
Figure 12: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages ≥18 Years, Select Years, 2015-2025
Figure 13: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages ≥18 Years, 2015
Figure 14: 8MM, Diagnosed Incident Cases of Breast Cancer by HER2 Status, Women, Ages ≥18 Years, 2015
Figure 15: 8MM, Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Stage at Diagnosis, Women, Ages ≥18 Years, 2015
Figure 16: 8MM, Proportion of HER2+/HR+ Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages ≥18 Years, 2015
Figure 17: 8MM, Proportion of HER2+/HR- Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages ≥18 Years, 2015
Figure 18: 8MM, Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Site of Metastasis, Women, Ages ≥18 Years, 2015
Figure 19: 8MM, Diagnosed Incident Cases of HER2-/HR+ Invasive Breast Cancer by Stage at Diagnosis, Women, Ages ≥18 Years, 2015
Figure 20: 8MM, Proportion of HER2-/HR+ Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages ≥18 Years, 2015
Figure 21: 8MM, Diagnosed Incident Cases of HER2-/HR+ Invasive Breast Cancer by Type of Biomarker Expression, Women, Ages ≥18 Years, 2015
Figure 22: 8MM, Diagnosed Incident Cases of TN Invasive Breast Cancer by Stage at Diagnosis, Women, Ages ≥18 Years, 2015
Figure 23: 8MM, Diagnosed Incident Cases of TN Invasive Breast Cancer with BRCA Expression, Women, Ages ≥18 Years, 2015
Figure 24: Active Late-Stage Clinical Trials for Herceptin
Figure 25: Active Late-Stage Clinical Trials for Tykerb
Figure 26: Active Late-Stage Clinical Trials for Perjeta
Figure 27: Active Phase III Clinical Trials for Kadcyla
Figure 28: Active Phase III Clinical Trials for Halaven
Figure 29: Active Phase III Clinical Trials for Abraxane
Figure 30: Overview of the Development Pipeline in HER2-Positive Breast Cancer
Figure 31: HER2-Positive Breast Cancer - Phase II-III Pipeline, 2015
Figure 32: Competitive Assessment of Late-Stage Pipeline Agents in HER2-Positive Breast Cancer, 2015-2025
Figure 33: Neratinib’s Clinical Development
Figure 34: Clinical and Commercial Positioning of Neratinib
Figure 35: Margetuximab’s Clinical Development
Figure 36: Clinical and Commercial Positioning of Margetuximab
Figure 37: Tucatinib’s Clinical Development
Figure 38: Clinical and Commercial Positioning of tucatinib
Figure 39: Pyrotinib’s Clinical Development
Figure 40: Clinical and Commercial Positioning of pyrotinib
Figure 41: Utidelone’s Clinical Development
Figure 42: Clinical and Commercial Positioning of utidelone
Figure 43: Ibrance’s Clinical Development
Figure 44: Clinical and Commercial Positioning of Ibrance
Figure 45: Onzeald’s Clinical Development
Figure 46: Clinical and Commercial Positioning of Onzeald
Figure 47: Global Sales ($m) of Branded Products for HER2-Positive Breast Cancer by Company, 2015-2025
Figure 48: Company Portfolio Gap Analysis in HER2-Positive Breast Cancer, 2013-2023
Figure 49: Global Sales for HER2-Positive Breast Cancer, by Region, 2015 and 2025
Figure 50: Global Sales for HER2-Positive Breast Cancer by Drug Class, 2015 and2025
Figure 51: Sales ($m) for HER2-Positive Breast Cancer in the US, by Drug Class, 2015-2025
Figure 52: Sales for HER2-Positive Breast Cancer in the 5EU, by Drug Class, 2015-2025
Figure 53: Sales for HER2-Positive Breast Cancer in Japan by Drug Class, 2015-2025
Figure 54: Sales for HER2-Positive Breast Cancer in China by Drug Class, 2015-2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report